Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 4/20 | 0.58 |
| ▸ | SRC | P12931 | 5/20 | 0.57 |
| ▸ | BRAF | P15056 | 10/20 | 0.55 |
| ▸ | EGFR | P00533 | 8/20 | 0.55 |
| ▸ | KIT | P10721 | 1/20 | 0.52 |
| ▸ | CDK1 | P06493 | 1/20 | 0.52 |
| ▸ | CDK2 | P24941 | 1/20 | 0.52 |
| ▸ | CDK8 | P49336 | 1/20 | 0.52 |
| ▸ | RET | P07949 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL546229 | 0.94 | MAPK14 (0.50) | ABL1SRCBRAFEGFR | |
| SCHEMBL545423 | 0.93 | MAPK14 (0.49) | ABL1SRCBRAFEGFRKIT | |
| SCHEMBL545439 | 0.88 | MAPK14 (0.44) | ABL1SRCBRAFEGFR | |
| SCHEMBL5416351 | 0.87 | RAF1 (0.45) | ABL1SRCBRAF | |
| SCHEMBL545217 | 0.87 | ABL1 (0.62) | ABL1SRCBRAFEGFRKIT | |
| SCHEMBL545637 | 0.83 | KDR (0.52) | ABL1SRCBRAFEGFRKIT | |
| SCHEMBL10199733 | 0.83 | KDR (0.42) | BRAF | |
| SCHEMBL10199956 | 0.83 | RAF1 (0.49) | BRAF | |
| SCHEMBL544927 | 0.82 | ABL1 (0.53) | ABL1SRCBRAFEGFRKIT | |
| SCHEMBL545253 | 0.81 | BRAF (0.58) | ABL1SRCBRAFCDK1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8110687-B2 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-02-07 | — | — | US | disclosed |
| US-8110687-B2 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-02-07 | — | — | US | disclosed |
| US-8110687-B2 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-02-07 | — | — | US | disclosed |
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MAP3K20, MAP3K1, MAP3K5 | ABL1 37/4885SRC 180/4885BRAF 215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.